A Resource for Healthcare and Social Services Professionals
Estimated time to complete: 1 hour 30 minutes
This activity reviews the HEALing Communities Study Evidence-Based Practices of naloxone, medications for opioid use disorder, and prescription opioid safety.
This activity reviews the HEALing Communities Study Evidence-Based Practices of naloxone, medications for opioid use disorder, and prescription opioid safety. In addition to brief evidence summaries, experienced health care professionals provide their perspective on and advice for implementing the practices to reduce opioid overdose deaths in highly affected communities.
Physicians, physician assistants, nurses, pharmacists, pharmacy techs and other interested health care professionals.
---- ----
Alexander Walley, MD, MSc, CME Course Director
Ilana Hardesty, MA, Planning Committee
David Morgan, RPH, Planning Committee
Trish Freeman, RPh, PhD, FAPhA, FNAP, Planning Committee
Conor Monks, Planning Committee
Members of the planning committee have no relevant financial relationships to disclose.
Phuong Huynh, MD
Faculty is Vice Chair of the Board of Directors at Ohio Physician Health Program and is a contracted physician reviewer for the Medical Review Institute of America. Faculty member does not plan on discussing unlabeled/investigational uses of a commercial product.
Laila Khalid, M.B.B.S., M.P.H.
Faculty member has no relevant financial relationships to disclose. Faculty member does not plan on discussing unlabeled/investigational uses of a commercial product.
Alyssa M. Peckham, PharmD, BCPP
Faculty is employed by Otsuka Pharmaceutical Companies as a Neuroscience Medical Science Liaison. Faculty member does not plan on discussing unlabeled/investigational uses of a commercial product.
Monica Roberts, PharmD
Faculty member has no relevant financial relationships to disclose. Faculty member does not plan on discussing unlabeled/investigational uses of a commercial product.
Barry Rose, BSPharm, Recovery Coach
Faculty member has no relevant financial relationships to disclose. Faculty member does not plan on discussing unlabeled/investigational uses of a commercial product.
Upon conclusion of this CE activity, participants should be able to:
HEALing Communities Study
Pharmacy Accreditation Information
Topic Designator: Disease State Management/Drug Therapy
Activity Type: Knowledge-based
Expires 12/15/2023
Pharmacist | UAN 0026-9999-21-085-H04-P
Pharmacy Technician | 0026-9999-21-085-H04-T
Accreditation
Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Massachusetts College of Pharmacy and Health Sciences designates this educational activity for a total of 1.5 contact hours (0.15 CEUs).
Requirements for Credit
Credit will not be issued to participants who do not complete the pre-test, post-test and evaluation. Credit may take up to 30 days to reflect on the CPE Monitor profile for the participants.
Statement of Disclosure
Massachusetts College of Pharmacy and Health Sciences adheres to the ACPE Standards for Integrity and Independence in Continuing Education. It is the policy of MCPHS University that the speakers and planning committee members disclose all financial relationships with ineligible companies, and that relevant conflicts of interest are mitigated. Speakers will disclose any unlabeled/unapproved use of drugs or devices during their presentation.
Alyssa M. Peckham is employed by Otsuka Pharmaceutical Companies as a Neuroscience Medical Science Liaison.
Barry Rose holds no relevant financial relationship with ineligible companies.
Laila Khalid holds no relevant financial relationship with ineligible companies.
Phuong Huynh is Vice Chair of the Board of Directors at Ohio Physician Health Program and is a contracted physician reviewer for the Medical Review Institute of America.
All MCPHS CE staff members have no relevant financial relationships with ineligible companies to disclose.
CME Accreditation Information
In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AMA Credit Designation Statement
Boston University Chobanian & Avedisian School of Medicine designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Date of Release: 3/18/2022
Date of Expiration: 12/31/2023
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships with ineligible companies that faculty, planners, authors and anyone who may be in control of content have been mitigated.
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.
This program meets the criteria of the Kentucky Board of Medical Licensure for HB1 Credit. Approval ID 0422-H1.5-UKHC1e.
Grayken Center for Addiction TTA is a program of Boston Medical Center (BMC), a 514-bed academic medical center located in Boston's historic South End and the largest safety-net hospital in New England.
The content on this site and the content presented by Grayken Center for Addiction TTA is intended solely to inform and educate healthcare and social service professionals, and shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional. The hospital, the program, and the contributors are not acting as health care providers or professional consultants on behalf of any specific patient and disclaim establishing a provider-patient relationship with any specific patient.